Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: LDK378

First Posted Date: 2015-05-21

Last Posted Date: 2021-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT02450903

Locations: 🇯🇵
Novartis Investigative Site, Koto ku, Tokyo, Japan

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease, COPD

Interventions: Drug: QBW251
Drug: Placebo

First Posted Date: 2015-05-20

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 92

Registration Number: NCT02449018

Locations: 🇵🇱
Novartis Investigative Site, Sobotka, Poland

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Phase 2

Completed

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)

Interventions: Biological: Tisagenlecleucel
Drug: Lymphodepleting chemotherapy

First Posted Date: 2015-05-15

Last Posted Date: 2024-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 115

Registration Number: NCT02445248

Locations: 🇺🇸
University of Chicago Medical Center Hematology and Oncology SC - CTL019B2207J, Chicago, Illinois, United States
🇺🇸
University of Kansas Cancer Center SC - CTL019C2201, Westwood, Kansas, United States
🇺🇸
MD Anderson Cancer Center SC, Houston, Texas, United States

and more 10 locations

CAR-T Long Term Follow Up (LTFU) Study

Phase 3

Recruiting

Conditions: Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Interventions: Genetic: Previously treated CAR-T patients

First Posted Date: 2015-05-15

Last Posted Date: 2025-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1400

Registration Number: NCT02445222

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 27 locations

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease, COPD

Interventions: Drug: QVA149
Drug: Placebo

First Posted Date: 2015-05-13

Last Posted Date: 2019-01-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT02442206

Locations: 🇩🇪
Novartis Investigative Site, Hannover, Germany

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Alpelisib
Drug: Placebo

First Posted Date: 2015-05-07

Last Posted Date: 2025-02-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 572

Registration Number: NCT02437318

Locations: 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States

and more 32 locations

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Phase 2

Completed

Conditions: Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

Interventions: Drug: MCS110
Drug: carboplatin
Drug: gemcitabine

First Posted Date: 2015-05-06

Last Posted Date: 2021-06-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT02435680

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇹🇷
Novartis Investigative Site, Istanbul, Turkey
🇺🇸
Massachusetts General Hospital Cancer Center SC, Boston, Massachusetts, United States

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

Phase 2

Completed

Conditions: Common Variable Immunodeficiency (CVID), APDS / PASLI

Interventions: Other: Placebo
Drug: CDZ173

First Posted Date: 2015-05-06

Last Posted Date: 2022-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT02435173

Locations: 🇺🇸
National Institute of Health NIH, Bethesda, Maryland, United States
🇬🇧
Novartis Investigative Site, Belfast, United Kingdom

AWARE - Chronic Urticaria

Completed

Conditions: Chronic Urticaria

First Posted Date: 2015-05-06

Last Posted Date: 2018-02-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 180

Registration Number: NCT02435238

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Phase 2

Completed

Conditions: B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: CTL019

First Posted Date: 2015-05-06

Last Posted Date: 2024-02-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT02435849

Locations: 🇺🇸
Childrens Hospital Los Angeles SC CTL019, Los Angeles, California, United States
🇺🇸
The Childrens Hospital of Philadelphia CHOP, Philadelphia, Pennsylvania, United States
🇪🇸
Novartis Investigative Site, Esplugues De Llobregat, Barcelona, Spain

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy